Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Apremilast - Celgene

Drug Profile

Apremilast - Celgene

Alternative Names: CC-10004; CC-1004; OTEZLA; Otezla

Latest Information Update: 11 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Celgene Corporation
  • Developer Baylor Research Institute; Celgene Corporation; Erasmus MC
  • Class Acetamides; Anti-inflammatories; Antineoplastics; Antipsoriatics; Isoindoles; Phthalimides; Skin disorder therapies; Small molecules; Sulfones
  • Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ulcerative colitis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Behcet's syndrome; Plaque psoriasis; Psoriatic arthritis
  • Phase III Ankylosing spondylitis; Psoriasis
  • Phase II Atopic dermatitis; Bullous pemphigoid; Eczema; Female genital diseases; Hidradenitis suppurativa; Palmoplantar pustulosis; Ulcerative colitis
  • No development reported Rheumatoid arthritis
  • Discontinued Asthma; Cancer; Crohn's disease

Most Recent Events

  • 27 Aug 2019 Phase II clinical trials in Female genital diseases in Norway (PO) (NCT03656666)
  • 26 Aug 2019 Celgene enters into an agreement with Amgen to divest apremilast
  • 15 Aug 2019 Celgene plans a phase II trial for Palmoplantaris pustulosis in Japan in September 2019 (NCT04057937)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top